Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer Consortium Phase II Study (NCI # 7003)

BACKGROUND: Bronchioloalveolar carcinoma (BAC), a subtype of non-small cell lung cancer (NSCLC), is a difficult disease to treat with low response rates with cytotoxic chemotherapy. Bortezomib, a proteasome inhibitor, has demonstrated objective responses in BAC patients in early phase clinical trial...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ramalingam, Suresh S., Davies, Angela M., Longmate, Jeffrey, Edelman, Martin J., Lara, Primo N., Vokes, Everett E., Villalona-Calero, Miguel, Gitlitz, Barbara, Reckamp, Karen, Salgia, Ravi, Wright, John J., Belani, Chandra P., Gandara, David R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3220078/
https://ncbi.nlm.nih.gov/pubmed/21716143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318225924c
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi